SynthesisBritish journal of haematology2020

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.

Panayotis Kaloyannidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.